U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C27H24FN3O
Molecular Weight 425.4974
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RWJ-67657

SMILES

OCCC#CC1=NC(=C(N1CCCC2=CC=CC=C2)C3=CC=NC=C3)C4=CC=C(F)C=C4

InChI

InChIKey=QSUSKMBNZQHHPA-UHFFFAOYSA-N
InChI=1S/C27H24FN3O/c28-24-13-11-22(12-14-24)26-27(23-15-17-29-18-16-23)31(25(30-26)10-4-5-20-32)19-6-9-21-7-2-1-3-8-21/h1-3,7-8,11-18,32H,5-6,9,19-20H2

HIDE SMILES / InChI

Molecular Formula C27H24FN3O
Molecular Weight 425.4974
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q16539|||Q8TDX0
Gene ID: 1432.0
Gene Symbol: MAPK14
Target Organism: Homo sapiens (Human)
1.0 µM [IC50]
Target ID: Q15759|||Q2XNF2
Gene ID: 5600.0
Gene Symbol: MAPK11
Target Organism: Homo sapiens (Human)
11.0 µM [IC50]
PubMed

PubMed

TitleDatePubMed
Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor.
2004
Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor.
2004 Mar 26
Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.
2008 Jun
The beta3-adrenoceptor agonist 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]-ethyl]phenyl]benzenesulfonamide (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human beta3-adrenoceptor.
2008 Nov
Patents

Patents

Substance Class Chemical
Created
by admin
on Sat Dec 16 18:29:31 GMT 2023
Edited
by admin
on Sat Dec 16 18:29:31 GMT 2023
Record UNII
MXN26D3ZUN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RWJ-67657
Code English
4-(4-FLUOROPHENYL)-2-(4-HYDROXY-1-BUTYNYL)-1-(3-PHENYLPROPYL)-5-(4-PYRIDYL)IMIDAZOLE
Systematic Name English
JNJ3026582
Code English
RWJ67657
Code English
JNJ-3026582
Code English
4-(4-(4-FLUOROPHENYL)-1-(3-PHENYLPROPYL)-5-(4-PYRIDYL)IMIDAZOL-2-YL)BUT-3-YN-1-OL
Systematic Name English
3-BUTYN-1-OL, 4-(4-(4-FLUOROPHENYL)-1-(3-PHENYLPROPYL)-5-(4-PYRIDINYL)-1H-IMIDAZOL-2-YL)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID40175867
Created by admin on Sat Dec 16 18:29:31 GMT 2023 , Edited by admin on Sat Dec 16 18:29:31 GMT 2023
PRIMARY
CAS
215303-72-3
Created by admin on Sat Dec 16 18:29:31 GMT 2023 , Edited by admin on Sat Dec 16 18:29:31 GMT 2023
PRIMARY
FDA UNII
MXN26D3ZUN
Created by admin on Sat Dec 16 18:29:31 GMT 2023 , Edited by admin on Sat Dec 16 18:29:31 GMT 2023
PRIMARY
MANUFACTURER PRODUCT INFORMATION
RWJ-67657
Created by admin on Sat Dec 16 18:29:31 GMT 2023 , Edited by admin on Sat Dec 16 18:29:31 GMT 2023
PRIMARY Selective p38α and p38β inhibitor (IC50 values are 1 and 11 μM respectively) that displays no activity at p38γ, p38δ and a range of other kinases. Potently inhibits TNF-α and IL-1β release (IC50 values are 3 and 11 nM respectively) and suppresses HIV-1 replication in T cells in vitro. Displays cardioprotective and anti-inflammatory activity in vivo. Orally active.
PUBCHEM
3008319
Created by admin on Sat Dec 16 18:29:31 GMT 2023 , Edited by admin on Sat Dec 16 18:29:31 GMT 2023
PRIMARY
ChEMBL
CHEMBL190333
Created by admin on Sat Dec 16 18:29:31 GMT 2023 , Edited by admin on Sat Dec 16 18:29:31 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
RWJ 67657 (4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol -2-yl]-3-butyn-1-ol) inhibited the release of TNF-alpha by lipopolysaccharide (a monocyte stimulus)-treated human peripheral blood mononuclear cells with an IC(50) of 3 nM, as well as the release of TNF-alpha from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (a T cell stimulus), with an IC(50) value of 13 nM.